{"id":"NCT01737268","sponsor":"Astellas Pharma Inc","briefTitle":"Long-term Study of FK949E in Elderly Bipolar Disorder Patients","officialTitle":"Long-term Study of FK949E in Elderly Patients -Long-term Study in Elderly Bipolar Disorder Patients With Major Depressive Episodes-","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10-29","primaryCompletion":"2016-06-29","completion":"2016-06-29","firstPosted":"2012-11-29","resultsPosted":"2017-10-31","lastUpdate":"2024-11-19"},"enrollment":20,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder","Elderly"],"interventions":[{"type":"DRUG","name":"FK949E","otherNames":["quetiapine"]}],"arms":[{"label":"FK949E Elderly Participants","type":"EXPERIMENTAL"}],"summary":"FK949E was administered to elderly bipolar disorder patients with major depressive episode for 52 weeks. Its safety, efficacy, and plasma concentration change were evaluated in an open-label manner.","primaryOutcome":{"measure":"Change From Baseline to Last Assessment in Treatment Period in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","timeFrame":"Baseline and week 52 (or the time of last assessment for participants who discontinued earlier)","effectByArm":[{"arm":"FK949E Elderly Participants","deltaMin":-13.1,"sd":11}],"pValues":[]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":14},"locations":{"siteCount":32,"countries":["Japan"]},"refs":{"pmids":["32792252"],"seeAlso":["https://www.astellasclinicalstudyresults.com/study.aspx?ID=214"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":20},"commonTop":["Somnolence","Thirst","Nasopharyngitis","Blood prolactin increased","Dizziness"]}}